Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $752M | $764M | $820M | $828M | $800M | $833M | $942M | $978M | $1.02B | $1.30B |
| Revenue growth | — | 1.7% | 7.3% | 1.0% | -3.3% | 4.1% | 13.1% | 3.8% | 4.1% | 27.4% |
| Gross profit | $239M | $248M | $267M | $265M | $257M | $271M | $285M | $298M | $313M | $400M |
| Gross margin | 31.8% | 32.5% | 32.5% | 32.0% | 32.1% | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% |
| Operating income | $85.7M | $97.9M | $98.9M | $83.2M | $69.2M | $74.9M | $79.0M | $71.8M | $53.3M | $110M |
| Operating margin | 11.4% | 12.8% | 12.1% | 10.1% | 8.6% | 9.0% | 8.4% | 7.3% | 5.2% | 8.5% |
| Net income | $82.7M | $64.6M | $64.9M | $54.7M | $33.6M | $54.4M | $49.2M | $32.6M | $2.42M | $48.3M |
| Net margin | 11.0% | 8.5% | 7.9% | 6.6% | 4.2% | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
| EPS (diluted) | $2.07 | $1.61 | $1.61 | $1.35 | $0.83 | $1.34 | $1.21 | $0.81 | $0.06 | $1.19 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $37.2M | $98.4M | $70.0M | $47.2M | $59.3M | $48.3M | $31.6M | $13.3M | $87.6M | $80.1M |
| Capital expenditures | $36.4M | $20.9M | $18.5M | $29.9M | $34.0M | $29.3M | $37.0M | $51.8M | $41.2M | $38.3M |
| Free cash flow | $866K | $77.5M | $51.5M | $17.3M | $25.3M | $19.0M | -$5.39M | -$38.5M | $46.4M | $41.8M |
| Dividends paid | $15.7M | $15.8M | $16.1M | $18.6M | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $33.6M | $56.1M | $29.2M | $57.6M | $36.3M | $50.2M | $74.2M | $41.3M | $70.6M | $68.0M |
| Total assets | $608M | $623M | $672M | $727M | $784M | $841M | $932M | $971M | $982M | $1.36B |
| Total liabilities | $517M | $472M | $487M | $511M | $596M | $603M | $669M | $689M | $726M | $1.08B |
| Long-term debt | — | — | — | — | — | — | $273M | $312M | $282M | — |
| Shareholders' equity | $90.5M | $151M | $185M | $216M | $188M | $239M | $262M | $283M | $257M | $286M |
| Retained earnings | $34.0M | $82.8M | $132M | $169M | $183M | $218M | $248M | $261M | $244M | $273M |
| Shares (wtd avg diluted) | 40.0B | 40.0B | 40.4B | 40.5B | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M | 40.7M |
Every figure is extracted from PHIBRO ANIMAL HEALTH CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.